Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

. The lesion is bright red and commonly referred to as a "strawberry mark".

Local complications may occur in the form of ulceration and critical localisations such as the eye area or the upper respiratory tract. These complications are the serious forms of the disease and represent 10% of total haemangioma occurrence, or 1% of births. First intention treatment is usually long-term systemic corticotherapy. The trouble with this kind of treatment is that it involves numerous and sometimes serious side-effects that are well known in infants.

About Pierre Fabre:

Pierre Fabre Laboratories, France's second biggest independent pharmaceutical laboratory, achieved a turnover of 1.75 billion euros in 2008. It employs nearly 10,000 people including 1,400 in the research sector. Its business sectors are ethical drugs, healthcare products and dermocosmetics with the brands Avene, Ducray/A Derma, Galenic/Elancyl, Klorane and Rene Furterer. Pierre Fabre Dermatologie, as part of Pierre Fabre Dermocosmetique, is specialised in prescription drugs.

In 2008, Pierre Fabre Medicament dedicated 33% of its annual turnover to R&D in five main therapeutic areas: oncology (priority sector with 50% of the overall R&D budget), Central Nervous System, cardiology, internal medicine/urology and dermatology. To find out more about Pierre Fabre Laboratories: http://www.pierre-fabre.com


'/>"/>
SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014 StemGenex® , the ... the US aimed at improving the lives of patients ... study for Parkinson’s disease. StemGenex believes that a ... therapy are paramount when providing care to patients with ... stem cell therapy accessible to the millions of individuals ...
(Date:7/23/2014)... 2014 /PRNewswire/ - BioAmber Inc. (NYSE: ... chemicals, today announced that the underwriters of its common ... purchase an additional 420,000 shares of common stock ... share, less underwriting discounts and commissions, in connection ... 2,800,000 shares of common stock, bringing the expected ...
(Date:7/23/2014)... , July 23, 2014  GrowBLOX Sciences, Inc. (OTCQB: ... that it is filing for two medical marijuana dispensary locations ... are in addition to the Clark County, Nevada ... special use permit, as previously announced.  GrowBLOX Sciences, ... be submitting two new applications for dispensaries in the ...
(Date:7/23/2014)... With the ability to record continuously at over ... 15 minutes, Fastec Imaging has brought the same ease-of-use of ... “Finally, a high speed camera that can be used as ... lives.” proclaims Matt Kearney, VP of Sales for Fastec Imaging. ... and simplify the traditionally complicated workflow of a high speed ...
Breaking Biology Technology:StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 2StemGenex® Gives Hope to Parkinson’s Patients through New Stem Cell Clinical Study 3BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 2BioAmber announces exercise in full of underwriters' option in connection with previously priced follow-on offering 3GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3
... /PRNewswire-FirstCall/ - On August 20, 2008,Oncothyreon Inc. (Nasdaq: ... a,letter from The Nasdaq Stock Market indicating that (i) ... on The NASDAQ Global Market,because it did not meet ... other things, that the market value of,its common stock ...
... with international ... and technology companies, TORONTO, Sept. 17 Aurillion, a ... Moreno as its vice president of sales and marketing. In ... grow the company,s business throughout the Americas, Europe,and Asia. He ...
... 17 Sigma-Aldrich Corporation,(Nasdaq: SIAL ) will be ... Wednesday, September 24th at 8:30 AM ET at the ... via live audio broadcast over the,Internet available at ... this file. For the webcast on, http://ir.sigmaaldrich.com users ...
Cached Biology Technology:Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards 2Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards 3Guillermo Moreno Named Aurillion's Vice President of Sales and Marketing 2
(Date:7/23/2014)... news release is available in German . ... and stability to cells, drive metabolic processes and transmit ... complex three-dimensional shapes. Scientists at the Max Planck Institute ... proteins can be constructed of similar amino acid chains ... that the proteins that exist today arose from common ...
(Date:7/23/2014)... BioCatch, the global leader in ... has been named in Gartner,s Market Guide for Online ... well-known Magic Quadrant for Web Fraud Detection. ... several vendors to deliver passive biometric analysis and predicted, ... feature of at least 30% of one-stop fraud detection ...
(Date:7/23/2014)... clinical use of induced pluripotent stem cell (iPSC) ... hindered by the risk of dysregulated cell growth, ... use etoposide treatment to halt teratoma formation in ... acute myocardial infarction, is demonstrated in an article ... peer-reviewed journal from Mary Ann Liebert, Inc., publishers. ...
Breaking Biology News(10 mins):Protein evolution follows a modular principle 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 2BioCatch Featured in Gartner's 2014 Online Fraud Detection Market Guide 3
... January 2014 Scientists from the Montreal Neurological ... two genes linked to hereditary Parkinson,s disease are ... The protective mechanism, which is reported in T ... arise from oxidative stress from mitochondria., "PINK1 and ...
... 21, JoVE, the Journal of Visualized Experiments , ... explored one of the most intriguing research questions facing ... protocol, titled Conducting Miller-Urey Experiments, is comprised of a ... Dr. Stanley Miller and Dr. Harold Urey in 1953. ...
... viral pathogen that typically infects plants has been found ... Researchers working in the U.S. and Beijing, China report ... journal of the American Society for Microbiology. The ... "resulted in the serendipitous detection of Tobacco Ringspot Virus, ...
Cached Biology News:Quality control of mitochondria as a defense against disease 2A 21st century adaptation of the Miller-Urey origin of life experiments 2Pathogenic plant virus jumps to honeybees 2
... Roches RTS AviTag E. coli Biotinylation Kit, Linear ... 100 E. coli expression kits. (Cat. No. 3 ... reagents to rapidly generate linear expression constructs by ... based on a combination of T7 RNA polymerase ...
... (GR) Competitor Assay Kits are ideal for ... The PolarScreen GR Competitor Assay Kits contain ... and one of the following proprietary fluorescent ... GS Red (red assay kit), or GS ...
... E. coli Biotinylation Kit, Plasmid is designed for ... coli expression kits. (Cat. No. 3 186 148, ... provides vectors for the easy introduction of a ... protein can be enzymatically mono-biotinylated by E. coli ...
... Exiqons LNA technology enables sensitive, fast ... on intact chromosomes. Short hybridisation ... fixed cells and chromosome spreads Multiplex ... Pre-validated probes Probes available ...
Biology Products: